Cargando…

Designing multi-target drugs /

"Multi-target drug discovery (MTDD) is an emerging area of increasing interest to the drug discovery community. Drugs that modulate several targets have the potential for an improved balance of efficacy and safety compared to single targets agents. Although there are a number of marketed drugs...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Morphy, Richard (Editor ), Harris, C. John (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cambridge, U.K. : RSC Publishing, [2012]
Colección:RSC drug discovery series ; 21.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000Ii 4500
001 KNOVEL_ocn789150271
003 OCoLC
005 20231027140348.0
006 m o d
007 cr |||||||||||
008 120425t20122012enka ob 001 0 eng d
040 |a UKRSC  |b eng  |e rda  |e pn  |c UKRSC  |d COO  |d UIU  |d MYG  |d KNOVL  |d YDXCP  |d N$T  |d ZCU  |d OHS  |d KNOVL  |d OCLCF  |d KNOVL  |d NLGGC  |d KNOVL  |d MHW  |d OCLCQ  |d MMU  |d E7B  |d OCLCQ  |d DEBSZ  |d OCLCQ  |d D6H  |d AGLDB  |d BUF  |d OCLCQ  |d OCLCO  |d VTS  |d RRP  |d NLE  |d UKMGB  |d STF  |d AU@  |d OCLCO  |d OCLCQ  |d OCLCO  |d ERF  |d OCLCQ  |d OCLCA  |d MM9  |d AJS  |d OCLCQ  |d OCLCA  |d OCLCO  |d OCL  |d OCLCQ  |d OCLCO 
015 |a GBB6G5358  |2 bnb 
016 7 |a 018021159  |2 Uk 
019 |a 785730758  |a 788647207  |a 810436453  |a 823728090  |a 843641057 
020 |a 9781849734912  |q (electronic bk.) 
020 |a 1849734917  |q (electronic bk.) 
020 |a 9781621981435  |q (electronic bk.) 
020 |a 1621981436  |q (electronic bk.) 
020 |a 9781849733625  |q (hardback) 
020 |a 1849733627  |q (hardback) 
029 1 |a AU@  |b 000049050036 
029 1 |a AU@  |b 000049632209 
029 1 |a AU@  |b 000050415578 
029 1 |a AU@  |b 000051449276 
029 1 |a AU@  |b 000058165432 
029 1 |a DEBSZ  |b 400458632 
029 1 |a DEBSZ  |b 450737136 
029 1 |a NLGGC  |b 34582234X 
029 1 |a NZ1  |b 14795170 
029 1 |a NZ1  |b 15023020 
029 1 |a NZ1  |b 15906267 
029 1 |a UKMGB  |b 018021159 
035 |a (OCoLC)789150271  |z (OCoLC)785730758  |z (OCoLC)788647207  |z (OCoLC)810436453  |z (OCoLC)823728090  |z (OCoLC)843641057 
037 |a T3671  |b Royal Society of Chemistry  |n http://www.rsc.org/spr 
050 4 |a RS420  |b .D47 2012eb 
060 4 |a QV 745 
072 7 |a MED  |x 023000  |2 bisacsh 
072 7 |a MED  |x 058170  |2 bisacsh 
072 7 |a MED  |x 071000  |2 bisacsh 
072 7 |a MED  |x 072000  |2 bisacsh 
082 0 4 |a 615.19  |2 23 
084 |a 35.00  |2 bcl 
084 |a 44.42  |2 bcl 
049 |a UAMI 
245 0 0 |a Designing multi-target drugs /  |c editors, J. Richard Morphy and C. John Harris. 
264 1 |a Cambridge, U.K. :  |b RSC Publishing,  |c [2012] 
264 4 |c ©2012 
300 |a 1 online resource (xxvii, 365 pages) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a RSC drug discovery series ;  |v 21 
504 |a Includes bibliographical references and index. 
505 0 |a Simple drugs do not cure complex diseases: the need for multi-targeted drugs -- Clinical need and rationale for multi-target drugs in psychiatry -- Drug molecules and biology: network and systems aspects -- Chemoinformatic approaches to target identification -- Designing multi-target drugs: in vitro panel screening, biological fingerprinting -- Phenotypic and in vivo screening: lead discovery and drug repurposing -- Target/s identification approaches: experimental biological approaches -- Historical strategies for lead generation -- In silico lead generation approaches in multi-target drug discovery -- The challenges of multi-target lead optimization -- Combination agents versus multi-targeted agents: pros and cons -- The discovery of lapatinib -- Identification and optimization of dual PI3K/mTOR inhibitors -- Discovery of HDAC-inhibiting multi-target inhibitors -- Targeting protein-protein interactions: dual inhibitors of Bcl-2 and Bcl-xL -- Discovery of the anti-psychotic drug, ziprasidone -- The rational design of triple reuptake inhibitors for the treatment of depression -- Discovery of multi-target agents for neurological diseases via ligand design -- Designing drugs with dual activity: novel dual angiotensin II and endothelin receptor antagonists -- Ethyl urea inhibitors of the bacterial type II topoisomerases DNA gyrase (GyrB) and topoisomerase IV (ParE). 
520 |a "Multi-target drug discovery (MTDD) is an emerging area of increasing interest to the drug discovery community. Drugs that modulate several targets have the potential for an improved balance of efficacy and safety compared to single targets agents. Although there are a number of marketed drugs that are thought to derive their therapeutic benefit by virtue of interacting with multiple targets, the majority of these were discovered accidentally. Written by world renowned experts, this is the first book to gather together knowledge and experiences of the rational discovery of multi-target drugs. It describes the current state of the art, the achievements and the challenges of the field and importantly the lessons learned by researchers to date and their application to future MTDD."--  |c Provided by publisher. 
588 0 |a Online resource; title from resource home page (ebrary, viewed November 2, 2015). 
590 |a Knovel  |b ACADEMIC - Pharmaceuticals, Cosmetics & Toiletries 
650 0 |a Drugs  |x Design. 
650 0 |a Drug targeting. 
650 0 |a Polypharmacy. 
650 1 2 |a Drug Design 
650 2 2 |a Polypharmacy 
650 2 2 |a Drug Delivery Systems 
650 2 2 |a Molecular Targeted Therapy  |x methods 
650 6 |a Médicaments  |x Conception. 
650 6 |a Médicaments  |x Ciblage. 
650 6 |a Polypharmacie. 
650 7 |a Chemistry.  |2 bicssc 
650 7 |a MEDICAL  |x Drug Guides.  |2 bisacsh 
650 7 |a MEDICAL  |x Nursing  |x Pharmacology.  |2 bisacsh 
650 7 |a MEDICAL  |x Pharmacology.  |2 bisacsh 
650 7 |a MEDICAL  |x Pharmacy.  |2 bisacsh 
650 7 |a Polypharmacy  |2 fast 
650 7 |a Drug targeting  |2 fast 
650 7 |a Drugs  |x Design  |2 fast 
700 1 |a Morphy, Richard,  |e editor. 
700 1 |a Harris, C. John,  |e editor. 
776 0 8 |i Print version:  |t Designing multi-target drugs.  |d Cambridge : Royal Society of Chemistry, 2012  |z 9781849733625  |w (OCoLC)779245878 
830 0 |a RSC drug discovery series ;  |v 21. 
856 4 0 |u https://appknovel.uam.elogim.com/kn/resources/kpDMTD0003/toc  |z Texto completo 
938 |a ebrary  |b EBRY  |n ebr10627657 
938 |a EBSCOhost  |b EBSC  |n 519373 
938 |a YBP Library Services  |b YANK  |n 9972017 
994 |a 92  |b IZTAP